ESC: Merck’s Steglatro shows limited promise with heart failure hospitalization data
Late to the party against its SGLT2 diabetes rivals, Merck & Co.’s Steglatro has also tracked way behind in the class’ growing presence in heart failure. Now, the drugmaker has posted new data showing Steglatro could, in fact, show benefits in that indication—but it’s a limited window into the future. Steglatro cut heart failure patients’ risk… Read More »